Clinical trial: A primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 1, 2009, Pages 38-45

  Jack, K ^a   Willott, S ^a   Manners, J ^a   Varnam, M A ^a   Thomson, B J ^a,b  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; HEPATITIS C ANTIBODY; METHADONE; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL NURSE SPECIALIST; CLINICAL TRIAL; EVALUATION; FEASIBILITY STUDY; FEMALE; HEALTH CARE DELIVERY; HEPATITIS C; HUMAN; INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SAFETY;

ADULT; ALGORITHMS; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG USERS; FEMALE; GREAT BRITAIN; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; NURSE CLINICIANS; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57649222622     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03872.x     Document Type: Article

References (22)

1. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003 362 : 2095 3100.
2. Sharma P, Lok A. Viral hepatitis and liver transplantation. Semin Liver Dis 2006 26 : 285 97.
3. Health Protection Agency. Hepatitis C in England: An Update. Annual Report. London : Health Protection Agency, 2007.
4. Sweeting MJ, De Angelis D, Brant L, Harris HE, Mann AG, Ramsay ME. The burden of hepatitis C in England. J Viral Hepat 2007 14 : 570 6.
5. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007 14 : 107 15.
6. Hickman M, Hope V, Brady T, et al. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepat 2007 14 : 645 52.
7. Department of Health. Hepatitis C Strategy for England. London : Department of Health Publications, 2002.
8. Irving WL, Smith S, Cater R, et al. Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens. J Viral Hepat 2006 4 : 264 71.
9. Ishak KG, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696 9.
10. Thomson BJ, Kwong G, Ratib S, et al. Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management. J Viral Hepat 2008 15 : 271 8.
11. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet 2002 360 : 1478 83.
12. Micallef JM, Macdonald V, Jauncey M, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007 14 : 413 8.
13. Booth JC, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut 2001 49 (Suppl. 1 1 21.
14. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 71.
15. NICE Technology Assessment number 106; TA106. 2006. Available at: http://www.nice.org.uk/TA106guidance (last accessed October 2008)
16. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001 34 : 188 93.
17. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003 37 : 443 51.
18. Van Thiel DH, Anantharaju A, Creech MS. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003 98 : 2281 8.
19. Jeffrey GP, MacQuillan G, Chua F, et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 2007 45 : 111 7.
20. Grebely J, Raffa JD, Meagher C, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007 22 : 1519 25.
21. Neal KR, Trent Hepatitis C Study Group, Ramsay S, Thomson BJ, Irving WL. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007 56 : 1098 104.
22. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community based linkage study. Lancet 2006 368 : 938 45.